Product Pipeline

Relevant Markets

Development Platform

Fact Sheet for Diabetes

World Market Size:


350 million children and adults Globally


$376 Billion dollars as of 2010

US Market Size:


25.8 million children and adults in the United States - 8.3% of the population - have diabetes.


18.8 million people


7.0 million people


79 million people*

New Cases:

1.9 million new cases of diabetes are diagnosed in people aged 20 years and older in 2010

Current Products:

Insulin Delivery Devices:

Insulin Pump, Pump Supplies, Insulin Pen, Insulin Syringes, Insulin Jet Injectors, Inhalable Insulin

Subcutaneous Insulin/ Analogues:

Lantus, Humulin, Humalog, Glucagon (emergency kit), Novolin, Novolog, Byetta, Liraglutide, Albiglutide, Taspoglutide, Lixenatide

Oral Anti Diabetic Drugs:

Amaryl, Precose, Glucophage, Januvia, Metformin, Avandia, Avandimet, Starlix, Prandin, Glucotrol, Diabinese, Glucamide, Glyset, Micronase Tolinase, Orinase, DiaBeta, Actos

Glucose Monitoring Devices Market:

Glucose Test Strips, Lanets, Blood Glucose Meter, Continuous Blood Glucose Monitors

Market Leaders:

3M Pharmaceuticals Abbott Laboratories, Animas Corporation, AstraZeneca, Sanofi- Aventis Pharmaceuticals Inc., Becton Dickinson and Company, Bristol Meyers Squibb Company, Eli Lilly, GlaxoSmithKline, Medtronic MiniMed, Merck and Co. Inc., Novartis, Novo Nordisk Pharmaceuticals Inc., Pfizer, Proctor and Gamble Pharmaceuticals, Roche Laboratories Inc., Takeda Pharmaceuticals

Market Overview:

Studies indicates that health spending associated with diabetes and pre-diabetes was about US$ 194 Billion in 2010.

Cost of Diabetes in 2007

  • $174 billion: Total costs of diagnosed diabetes in the United States in 2007
  • $116 billion for direct medical costs
  • $58 billion for indirect costs (disability, work loss, premature mortality)

Factoring in the additional costs of undiagnosed diabetes, prediabetes, and gestational diabetes brings the total cost of diabetes in the United States in 2007 to $218 billion.

  • $18 billion for people with undiagnosed diabetes
  • $25 billion for American adults with prediabetes
  • $623 million for gestational diabetes

Diabetes is a growing global epidemic. It has been estimated that around 52% of the adult population will have diabetes or pre-diabetes by 2020. 90% of people with prediabetes are unaware of their condition. Approximately 25% of the population with diabetes is also unaware of their condition. In the US alone, over 48 million prescriptions for biguanides such as metformin are written annually.

U.S. healthcare costs are drastically increasing because of Diabetes placing growing strain on the budgets of families, employers, states, and the federal government. Studies indicate that health spending associated with diabetes and pre-diabetes consumes approximately 7% of total U.S. health spending. Complications extending from Diabetes lead to high blood pressure, kidney disease, blindness, heart disease and stroke, nervous system disease, and even amputation.

Though many products exist in the current market as a therapeutic, no curative solutions have been developed to date. There are many international pharmaceutical companies spending billions on research annually to try to get to an effective cure. Many oral solutions currently available for patients have severe side effects and weaken the pancreas over time due to un-natural constant pressure to produce insulin. This sometimes provides more harmful outcomes in the longer term.

D-Helix Technology

Major pharmaceutical companies such as Eli Lilly, Roche, Sanofi, and many others have spent billions of dollars over the last decades developing injectable incretin hormones to improve glycemic control through glucose - stimulated insulin secretion (GSIS) in the in the body via activation of signaling pathways. Till date, the effector proteins which mediate incretin action in Beta cells remain poorly defined.

D-Helix has the exclusive commercial rights to a proprietary patented discovery that could result in a novel drug target for the treatment of type 2 diabetes. Mice with global knockout of the gene as well as B-cell specific deletion of the gene were generated. The results show that the deficiency in this gene impairs Glucose Induced Insulin Secretion and abolishes the effect of Byetta, a drug currently marketed by Eli Lilly, on GSIS. The overexpression of our identified gene in mice could enhance the effects of Byetta. and other diabetes therapeutics already marketed. Due to the discovery of the effects of the gene on GSIG and the role B-cells, this technology could be used to screen for novel anti-diabetes drugs.

Future Scope

Next steps would be to identify a major pharmaceutical partner specializing in this area and co-developing a more effective and economical product in the market than those available today.